Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
Total Valuation
Soleno Therapeutics has a market cap or net worth of $3.21B. The enterprise value is $1.74B.
Market Cap$3.21B
Enterprise Value$1.74B
Share Statistics
Soleno Therapeutics has 45.86M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45.86M
Owned by Insiders12.10%
Owned by Instutions1.05%
Financial Efficiency
Soleno Therapeutics’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-71.74%
Return on Assets (ROA)-53.13%
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00%
Revenue Per Employee$0
Profits Per Employee-$1,911,413.043
Employee Count92
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Soleno Therapeutics is -10.27. Soleno Therapeutics’s PEG ratio is -0.12.
PE Ratio-10.27
PS Ratio0.00
PB Ratio7.37
Price to Fair Value7.37
Price to FCF-26.05
Price to Operating Cash Flow-26.14
PEG Ratio-0.12
Income Statement
In the last 12 months, Soleno Therapeutics had revenue of $0.00 and earned -$175.85M in profits. Earnings per share was -$4.26.
Revenue$0.00
Gross Profit-$984.00K
Operating Income-$183.96M
Pretax Income-$175.85M
Net Income-$175.85M
EBITDA-173.63M
Earnings Per Share (EPS)-4.26
Cash Flow
In the last 12 months, operating cash flow was -$69.10M and capital expenditures -$218.00K, giving a free cash flow of -$69.31M billion.
Operating Cash Flow-$69.10M
Free Cash Flow-$69.31M
Free Cash Flow per Share-$1.51
Dividends & Yields
Soleno Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-3.84%
Earnings Yield-9.74%
Stock Price Statistics
Beta-0.49
52-Week Price Change86.61%
50-Day Moving Average54.36
200-Day Moving Average50.71
Relative Strength Index (RSI)62.10
Average Volume (3m)1.93M
Important Dates
Soleno Therapeutics upcoming earnings date is May 13, 2025, TBA.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Soleno Therapeutics as a current ratio of 15.68, with Debt / Equity ratio of 0.01
Current Ratio15.68
Quick Ratio15.68
Debt to Market Cap<0.01
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Soleno Therapeutics has paid $1.19M in taxes.
Income Tax$1.19M
Effective Tax Rate0.00%
Enterprise Valuation
Soleno Therapeutics EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -24.83.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-24.83
EV to Operating Cash Flow-24.91
Balance Sheet
Soleno Therapeutics has $291.44M in cash and marketable securities with $52.83M in debt, giving a net cash position of -$238.61M billion.
Cash & Marketable Securities$291.44M
Total Debt$52.83M
Net Cash-$238.61M
Net Cash Per Share-$5.20
Tangible Book Value Per Share$5.93
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Soleno Therapeutics is $99.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$99.13
Price Target Upside41.65%
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast
EPS Growth Forecast-43.20%